Daily Cosmetic Research Analysis
Three impactful studies span dermatologic oncology, ophthalmic surgery, and environmental safety of cosmetic ingredients. Multicenter data support electronic brachytherapy as a well-tolerated, cosmetically favorable option for low-risk non-melanoma skin cancer, while a large office-based series demonstrates safe, cost-effective pterygium surgery with high patient satisfaction. A critical review synthesizes ecotoxicological risks of sunscreen UV filters, highlighting research gaps critical to saf
Summary
Three impactful studies span dermatologic oncology, ophthalmic surgery, and environmental safety of cosmetic ingredients. Multicenter data support electronic brachytherapy as a well-tolerated, cosmetically favorable option for low-risk non-melanoma skin cancer, while a large office-based series demonstrates safe, cost-effective pterygium surgery with high patient satisfaction. A critical review synthesizes ecotoxicological risks of sunscreen UV filters, highlighting research gaps critical to safer formulation and regulation.
Research Themes
- Non-surgical dermatologic oncology and cosmetic outcomes
- Office-based ophthalmic surgery safety and cost-effectiveness
- Environmental safety of cosmetic sunscreen UV filters
Selected Articles
1. Ecotoxicological effects of sunscreen derived organic and inorganic UV filters on marine organisms: A critical review.
This critical review synthesizes evidence from 111 studies on the ecotoxicology of sunscreen UV filters, showing a predominant focus on organic filters (notably oxybenzone) and frequent use of oxidative-stress endpoints in bivalves. It highlights methodological gaps—limited taxa, life stages, and environmental realism—and recommends incorporating dietary exposure and UV lighting in future experiments to better inform safer formulation and policy.
Impact: Given global sunscreen use and regulatory scrutiny, this synthesis will likely shape toxicological testing standards and ingredient reformulation toward lower environmental impact.
Clinical Implications: Dermatology and public health stakeholders should consider the environmental profiles of UV filters when advising on sunscreen use and when selecting ingredients, balancing skin cancer prevention with ecosystem health.
Key Findings
- Screened 111 peer-reviewed studies (Jan–Oct 2024); 60% assessed organic UV filters, with oxybenzone the most studied (57%).
- Inorganic filters comprised 40% of studies; bivalves were the most commonly tested taxa (24%).
- Oxidative stress assays dominated (≈40%) across both organic and inorganic studies.
- Key gaps include limited taxa/life-stage coverage and lack of realistic exposure conditions; future work should include dietary uptake and UV lighting.
Methodological Strengths
- Comprehensive multi-database retrieval and quantitative description of topic distribution.
- Clear articulation of methodological gaps and actionable recommendations for experimental realism.
Limitations
- Not presented as a PRISMA-compliant systematic review; no formal meta-analysis.
- Temporal scope limited to 2024 publications may omit earlier foundational studies.
Future Directions: Adopt standardized, environmentally realistic test systems incorporating UV light, dietary uptake, and multiple life stages across diverse taxa to refine risk assessment and guide ingredient reformulation.
Sunscreens are topical personal care products that provide protection against the sun's ultraviolet A (UVA) and ultraviolet B (UVB) radiation. Ultraviolet (UV) filters are compounds added to sunscreens to block, absorb, or reflect the sun's UV rays, but are of major emerging concern due to their widespread use and global distribution. They pose a significant risk to marine organisms owing to their chemical properties, including high lipophilicity which increases their bioavailability. The present review identifies and summarises the factors that contribute to UV filter pollution, their sources, pathways, and effects on marine organisms. We identify and evaluate the current knowledge base and gaps pertaining to their effects. Here, we retrieved 111 peer-reviewed articles from four academic search engines between January and October 2024 with the topic search relating to UV filters, sunscreen and ecotoxicology. Most publications (60 %) focused on the biological effects of organic UV filters, with oxybenzone (benzophenone-3) being the most studied (57 %). Fewer publications assessed the biological effects of inorganic UV filters (40 %). Throughout all search results, the most commonly tested species were in the class of bivalvia (24 %) and oxidative stress based assays were the most popular (organic studies 40 %, inorganic studies, 39 %). To enhance understanding, future research should explore a broader range of organisms and life stages, considering dietary uptake and realistic environmental conditions, including the use of UV lighting in laboratory settings.
2. The Elekta Esteya
In a six-center phase IV cohort (205 patients/236 lesions), high-dose-rate electronic brachytherapy for low-risk NMSC achieved excellent/good cosmesis in 90–100% of assessments (slightly lower early post-therapy) with only one recurrence over a median 24.2 months. Acute erythema peaked at 1 month and resolved by 6 months; chronic toxicities were limited to low rates of hypopigmentation and telangiectasia.
Impact: Provides multi-center, longitudinal evidence supporting EBx as a non-surgical alternative with high cosmetic satisfaction and very low recurrence for low-risk NMSC.
Clinical Implications: EBx can be offered as a first-line non-surgical option for appropriately selected low-risk NMSC patients, especially those with surgical risk, cosmesis concerns, keloid tendency, wound-care limitations, or on anticoagulation.
Key Findings
- Excellent/good cosmesis in 90–100% of both HCP and patient ratings; HCP early (1–3 months) rating 83–87%.
- Only one recurrence among 236 lesions (0.42%) with median follow-up 24.2 months (max 73.5 months).
- Most common acute AE was erythema (34.1% at 1 month), resolving to 0% by 6 months; chronic hypopigmentation and telangiectasia occurred at low rates.
- Treatment schemes delivered 69–72 Gy (BED) across six centers, indicating feasibility and generalizability.
Methodological Strengths
- Multicenter cohort with standardized high-dose-rate EBx protocols and dual (HCP and patient) cosmetic assessments.
- Longitudinal follow-up up to 73.5 months capturing both acute and chronic toxicities.
Limitations
- Non-randomized cohort without a surgical comparator; potential selection bias.
- Heterogeneity in fractionation schemes and a median follow-up of ~2 years may limit long-term recurrence assessment.
Future Directions: Prospective randomized comparisons versus Mohs surgery or standard excision focusing on long-term control, cosmesis, and cost-effectiveness; optimization of fractionation for specific lesion locations.
PURPOSE: The study was conducted to provide support for the delivery of electronic brachytherapy (EBx) in patients with low-risk non-melanoma skin cancer (NMSC) lesions who prefer and benefit a non-surgical treatment. MATERIAL AND METHODS: This study included 205 patients with a total of 236 lesions. Six centers participated in this study using high-dose-rate EBx in NMSC. Eligible patients had pathologically confirmed basal cell or squamous cell carcinoma of clinical stage Tis, T1, or T2, with two or fewer high-risk clinical or pathologic features. Treatment doses were chosen from a set of fractionation schemes delivering 69-72 Gy (BED). Maximum follow-up was 5 years. RESULTS: The median age was 74 (range, 56-96) years, and 62% of the subjects were males and 38% females. The median follow-up was 24.2 months, with a maximum of 73.5 months. Healthcare professional (HCP) and patient-rated cosmesis were rated excellent/good (E/G) by both groups at 90-100% rates, except for HCP ratings of 1-3 months post-EBx, where cosmesis was rated 83-87% E/G. Erythema was the most common acute adverse event (34.1% at 1 month), rebounding back to zero by 6 months. There was a single lesion recurrence. CONCLUSIONS: This report provides additional phase IV clinical data on NMSC treated with electronic brachytherapy. With 2-year median follow-up, there was one recurrence (0.42%). Patients tolerated the treatments well, as evidenced by strong and longitudinal scores on the skin cancer index as well as cosmetic evaluations performed by both patients and healthcare providers. Adverse rates were low, except for expected acute erythema, chronic hypopigmentation, and telangiectasia. The study provides additional information on EBx delivery for low-risk NMSC lesions in patents who prefer non-surgical treatment, especially those at risk for surgical complications, surgical cosmesis issues, keloid formation, wound care issues, and use of anticoagulant therapy.
3. The Safety of Office-Based Pterygium Surgery.
In 1071 office-based pterygium surgeries, 1-year recurrence was 2.04% with no infections, pain scores under 1, and cosmetic satisfaction over 88%. Average cost was $1,795, substantially lower than surgical centers and hospitals, supporting office-based surgery as a safe, cost-effective model.
Impact: Large-scale real-world evidence supports shifting a common ocular surface procedure to office settings without compromising safety or cosmetic outcomes while reducing costs.
Clinical Implications: Office-based pterygiectomy can be adopted with topical anesthesia and oral sedation, maintaining low recurrence and high satisfaction while reducing facility costs; avoid epinephrine in peribulbar anesthesia to mitigate CRAO risk.
Key Findings
- Among 393 cases with 1-year data, recurrence was 2.04%, dellen 3.05%, granuloma 3.82%, and ptosis 2.6%; no infections.
- Patient-reported pain remained <1 peri- and postoperatively; cosmetic satisfaction exceeded 88% at 1 year.
- Average office-based cost was $1,795 versus $3,812.50 at surgical centers and $5,562 at hospitals.
- One CRAO linked to epinephrine-containing peribulbar anesthesia prompted removal of epinephrine from the regimen.
Methodological Strengths
- Very large case series with standardized workflow and multiple scheduled follow-ups up to 1 year.
- Comprehensive outcomes including complications, pain, cosmetic satisfaction, and detailed cost comparison.
Limitations
- Retrospective design without randomized or concurrent OR-based control; potential selection and reporting bias.
- Only 393/1015 cases had 1-year follow-up data; two-surgeon experience may limit generalizability.
Future Directions: Prospective comparative trials versus ambulatory center/hospital settings; standardized protocols to minimize recurrence and optimize cosmesis; broader multi-operator validation.
PURPOSE: Hospital and ambulatory eye surgical procedures continue to transition to the office setting. Pterygium surgery is the most commonly performed ocular surface surgical procedure in the world. No studies to date have evaluated its safety in the office-based surgical setting. Our study evaluates the safety, complication rate, cost-savings, and cosmetic satisfaction of office-based pterygiectomy. DESIGN: Retrospective case series. METHODS: A retrospective review was performed. Procedures were performed in an office-based suite with a Zeiss surgical microscope by two board-certified ophthalmologists under topical anesthesia and oral sedation. Over a 3 year period (2013-2016), 1071 office-based pterygiectomies were performed. Follow-up was performed via in-person office visits. Data collected included: date of service; location of pterygium (nasal, temporal, or both); primary or recurrent; use of mitomycin C, fibrin glue, and amniotic membrane; preoperative and postoperative refraction; intraocular pressure (IOP); endothelial cell density (ECD); patient-reported pain (as measured by an eleven-point visual analog scale, 0-10); cosmetic satisfaction; intraoperative surgical time; speculum width; incidence of ptosis (defined as a decrease in MRD1 by 2 mm) postoperatively at 12 weeks and 1 year and postoperative complications. Postoperative measures were checked at 1 day, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year. The average operational and procedural costs were compared between in-office and comparable surgical centers and academic hospital cases in our area. RESULTS: A total of 1015 pterygia from 992 eyes were examined postoperatively. One case of central retinal artery occlusion due to peribulbar anesthetic injection with epinephrine at postoperative week 2 was noted, leading to the removal of epinephrine from the anesthetic regimen. At the 1-year follow-up, 393 pterygium cases in 343 eyes were assessed. One-year complication rates included overall recurrence (N = 8/393; 2.04%), dellen (N = 12/393; 3.05%), and granuloma (N = 15/393; 3.82%), ptosis 2.6% (N = 9/343). There were no cases of infection. Patient-reported pain scores remained less than 1.0 peri‑ and postoperatively, and cosmetic satisfaction was greater than 88% at 1 year. The average cost of office-based pterygium surgery was $1795 ($1700-$1890, depending on supplies used). In comparison, the costs at local surgical centers and hospitals were $3812.50 ($2625-$5000) and $5562 ($5095-$6029), respectively. CONCLUSION: Office-based pterygiectomy is safe, cost-effective, and offers low recurrence rates and high patient satisfaction.